Results 191 to 200 of about 134,666 (283)

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, EarlyView.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Recommended Tool Compounds: Isoform- and Class-Specific Histone Deacetylase Inhibitors. [PDF]

ACS Pharmacol Transl Sci
Schäker-Hübner L, Hansen FK.
europepmc   +1 more source

Selective targeting of cortactin tandem repeat acetylation by human lysine deacetylases

The FEBS Journal, EarlyView.
Cortactin function is regulated by acetylation at several lysine residues within its tandem repeat region. Using genetic code expansion to generate cortactin variants containing precisely defined acetylation marks, we show that HDAC6 is the primary enzyme removing these modifications, with SIRT1 and SIRT2 also acting at selected sites but with lower ...
Jan Komarek, Miroslava Vosahlikova, Zsofia Kutil, Zora Novakova, Julia Kudlacova, Ruzena Tuckova, Marat Meleshin, Barbora Havlinova, Pavlina Jaklova, Jana Ptackova, Cordelia Schiene‐Fischer, Mike Schutkowski, Cyril Barinka   +12 more
wiley   +1 more source

Phosphatidylinositol-3-Kinase (PI3K) and Histone Deacetylase (HDAC) Multitarget Inhibitors: An Update on Clinical and Preclinical Candidates. [PDF]

Pharmaceuticals (Basel)
Lima ADS, Lima LM.
europepmc   +1 more source

Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia

The FEBS Journal, EarlyView.
Genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Fortunately, menin inhibition has emerged as a promising new class of targeted therapy.
Lydia Elaine Roets, Graeme Greenfield, Katrina Mairead Lappin   +2 more
wiley   +1 more source

From bench to bedside: combining HDAC inhibitors with standard therapies in rhabdomyosarcoma treatment. [PDF]

Front Cell Dev Biol
Macrì E, Attili M, Locatelli F, Marampon F, Pomella S.   +4 more
europepmc   +1 more source

The R203W substitution drives PACS‐1 syndrome by disrupting intramolecular regulation

The FEBS Journal, EarlyView.
The middle region (MR) of PACS‐1 controls engagement with specific partner proteins. This manuscript presents the structure of the Furin binding region (FBR) and how interactions with partners are regulated through the interplay between a basic patch in the FBR and an acidic cluster in the MR.
Troy C. Krzysiak, In‐Ja L. Byeon, Ryan Ponticelli, Mary E. Lucas, Lariah Thompson, Christopher DeHaven, Gary Thomas, Angela M. Gronenborn   +7 more
wiley   +1 more source

HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives. [PDF]

RSC Adv
Abdallah AE.
europepmc   +1 more source

Disruption of iron metabolism resulting from Dmt1/Slc11a2 deficiency compromises Notch protein degradation and transcriptional activation

The FEBS Journal, EarlyView.
Divalent metal transporter 1 (Dmt1) maintains iron homeostasis and lysosomal proteostasis required for physiological Notch receptor–ligand signaling. Dmt1 loss lowers iron storage capacity (ferritin), increasing intracellular Fe2+, driving ROS and lipid peroxidation, and leading to lysosomal/mitochondrial dysfunction.
Rui Zhang, Somaieh Ahmadian, Jolanda Piepers, Florian Bock, Tom Keulers, Marc A. Vooijs   +5 more
wiley   +1 more source

Palladium-catalysed synthesis of small-molecule epigenetic inhibitors as anticancer therapeutics. [PDF]

J Enzyme Inhib Med Chem
Sharma R, Rana M, Thakur A, Ojha R, Mousavi SM, Dhingra A, Nepali K.   +6 more
europepmc   +1 more source